[Visual prognosis of branch retinal vein occlusion with macular edema]
- PMID: 16642947
[Visual prognosis of branch retinal vein occlusion with macular edema]
Abstract
Purpose: To evaluate visual outcome and prognostic factors of branch retinal vein occlusion (BRVO) combined with macular edema, when no aggressive treatment is performed.
Patients and methods: We retrospectively analyzed 80 eyes of 80 patients of BRVO associated with macular edema. The average age was 65.7 years and the average follow-up period was 32.1 months. Oral or instillation drug therapy was conducted in 42 eyes and peripheral scatter argon laser photocoagulation for the capillary non-perfusion area was carried out in 61 eyes (photocoagulation for macula was excluded).
Results: Baseline visual acuity(BVA) and final visual acuity(FVA) had a positive correlation (r= 0.60, p< 0.001). 69% of eyes with BVA of 0.1 or less remained at FVA 0.1 or worse, while 78% of eyes with BVA of 0.8 or better maintained FVA of 0.8 or better. Visual acuity improved in 26%, remained unchanged in 54%, and deteriorated in 20% during follow-up periods. In the eyes with visual loss the deterioration occurred in the early periode from onset, but in the eyes with visual improvement the visual acuity tended to improve steadily.
Conclusions: Even if macular edema occurs, some of the BRVO eyes can attain good visual acuity. However, we recommend aggressive treatment when the best-corrected acuity is poor or when the visual acuity worsens gradually, because there is a strong possibility that the visual prognosis will be poor.
Similar articles
-
[Analysis of visual prognosis and correlative factors in retinal vein occlusion].Zhonghua Yan Ke Za Zhi. 2002 Feb;38(2):98-102. Zhonghua Yan Ke Za Zhi. 2002. PMID: 11955310 Chinese.
-
Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation.Retina. 2008 Mar;28(3):465-72. doi: 10.1097/IAE.0b013e318154b9d1. Retina. 2008. PMID: 18327140
-
[Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease].Klin Monbl Augenheilkd. 2013 Apr;230(4):396-400. doi: 10.1055/s-0032-1328365. Epub 2013 Apr 29. Klin Monbl Augenheilkd. 2013. PMID: 23629790 Clinical Trial. German.
-
Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion.Jpn J Ophthalmol. 2018 May;62(3):265-273. doi: 10.1007/s10384-018-0586-5. Epub 2018 Mar 23. Jpn J Ophthalmol. 2018. PMID: 29572577 Review.
-
Macular edema.Int Ophthalmol Clin. 1999 Fall;39(4):1-18. doi: 10.1097/00004397-199903940-00003. Int Ophthalmol Clin. 1999. PMID: 10709579 Review. No abstract available.
Cited by
-
Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1635-41. doi: 10.1007/s00417-009-1151-1. Epub 2009 Jul 26. Graefes Arch Clin Exp Ophthalmol. 2009. PMID: 19633982
-
Possible effects of internal limiting membrane peeling in vitrectomy for macular vein occlusion.Jpn J Ophthalmol. 2010 Jan;54(1):61-5. doi: 10.1007/s10384-009-0750-z. Epub 2010 Feb 12. Jpn J Ophthalmol. 2010. PMID: 20151278
-
OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol. 2010 Nov;248(11):1567-72. doi: 10.1007/s00417-010-1419-5. Epub 2010 Jul 2. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20596719
-
Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol. 2010 Feb;248(2):155-9. doi: 10.1007/s00417-009-1167-6. Epub 2009 Sep 9. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 19763601
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources